Macrolide Appoints Two New Board Members

WATERTOWN, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a company developing novel antibiotics for drug-resistant, hospital-acquired infections, today announced the appointment of two new members to its Board of Directors. Mr. Christopher Viehbacher, Managing Partner at Gurnet Point Capital and Chairman of Boston Pharmaceuticals, and Dr. Markus Goebel, Managing Director at Novartis Venture Fund, bring a wealth of experience in drug development and portfolio planning.

“We are delighted to welcome Chris and Markus to our Board,” commented Macrolide Pharmaceuticals CEO Dr. Lawrence Miller. “As we advance our lead candidates into and through clinical trials, their expertise will be of great value in helping shape our strategy.”

Mr. Viehbacher previously served as the CEO of Sanofi-Aventis and Executive Chair of the Board of Genzyme, and President of North American Pharmaceuticals for GlaxoSmithKline. Previously, he was with GlaxoSmithKline and its antecedents for 20 years in various key global and North American roles. He currently serves on a number of Boards including PureTech Health plc, Crossover Health, Inncoll plc and BEFORE Brands. Mr. Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide and the Légion d'Honneur, France's highest civilian award. Mr. Viehbacher graduated from Queen's University, Ontario, with a degree in Commerce.

Dr. Goebel previously served as Head of Novartis Pharmaceutical Corporate M&A and Head Nervous System Business Development & Licensing. A physician by training and certified in hematology/ oncology, Dr. Goebel previously worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche before joining Novartis. Dr. Goebel received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley.

About Macrolide Pharmaceuticals
Macrolide Pharmaceuticals, based in Watertown, MA, is developing novel antibiotics for the treatment of serious, multi-drug resistant Gram-negative infections. The company’s core discovery and development program leverages a groundbreaking synthetic chemistry platform developed by Dr. Andrew Myers at Harvard University. Macrolide Pharmaceuticals’ lead program is in late preclinical development, and the company’s chemistry platform has the potential to be used to develop therapeutics to treat multiple infections conditions. For more information, please visit

Company and Media Contact
Macrolide Pharmaceuticals
Barry Wohl, 617-932-7481

Back to news